Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio

Recent News

Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Ointment USP, 0.1%

BUENA, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...

Learn More

Teligent, Inc. Executes $120 Million Financing Agreement

BUENA, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced t...

Learn More

Teligent, Inc. Receives Notification of Deficiency From NASDAQ Related to the Delayed Filing of Form 10-Q

BUENA, N.J. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), on November 13, 2018 received a standard ...

Learn More

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Investor Overview

There are no items to display.